Phase 4 Hepatitis B Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People over 18 years old who have liver cirrhosis and attended the hepatology clinic at Mercy Medical Center between September 2020 and July 2021
- People who do not have sufficient protection against Hepatitis B, based on a blood test result showing an anti-HBs level below 10 mIU/ml
Who may not be able to join:
- People who have had a serious allergic reaction to a previous dose of the Hepatitis B vaccine, any ingredient in the Hepatitis B vaccine, or yeast
- People who have previously been infected with Hepatitis B
- People who have had a liver transplant
- People who are under 18 years old
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Paul Thuluvath, MD, Mercy Medical Center
Phone: (714)-400-1331
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The rates of seroconversion after two doses of Heplisav-B given at 0 and 4 weeks versus three doses of Heplisav-B given at 0, 4 weeks, and 8 weeks.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.